FOLH1 and prostate carcinoma: Prostate-specific membrane antigen (PSMA), a prostate cancer specific cell surface biomarker, can be used for prostate cancer targeting, since it is highly overexpressed in nearly all types of prostate cancer but demonstrated only limited expression in normal tissues.